Today TheSAY was elated to have delegates from Reliance Life Sciences who have the highest number of biosimilars under development globally.
We held a productive discussion around business expansion in the CIS & African markets and creating a detailed plan for future vaccine projects with Reliance.
In attendance were, KV Subramaniam (CEO), KV Balasubramaniam (Advisor - vaccines), Muthukrishnan R (Regional Head- ME & Africa) & Sivaraman Vasudevan (Vice President- International Business) from Reliance Life Sciences, along with our Dr. Noushad Abdurahiman M.D.(CEO), Balaji Anbalagan (Pharma Director)